Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional Triamcinolone for Idiopathic Granulomatous Mastitis
NCT06985537Phase 1Not yet recruiting
- Sponsor
- Assiut University
- Start
- Jun 2025
- Primary completion
- Jan 2026
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, open-label, single-arm trial of triamcinolone in idiopathic granulomatous mastitis (IGM), sponsored by Assiut University. Primary endpoints: Clinical Resolution Rate at 12 Weeks Post-Treatment and Reduction in Lesion Size at 12 weeks. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
triamcinolone
03
Conditions
idiopathic granulomatous mastitis (IGM)
Beyond the preview
Go deeper on NCT06985537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06985537.